memantine has been researched along with Intraocular Pressure in 20 studies
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preglaucomatous DBA/2J mice received memantine (5 mg/kg, intraperitoneal injection, twice daily for 3 months) and IOP in the eyes was measured monthly." | 7.75 | Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. ( Angert, M; Duong-Polk, KX; Ellisman, MH; Ju, WK; Kim, KY; Lindsey, JD; Weinreb, RN, 2009) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 7.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 7.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| " Daily oral dosing for approximately 15 months with 4." | 5.31 | Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. ( Chun, T; Feldmann, B; Hare, W; Lai, R; Ruiz, G; Ton, H; Wheeler, L; Wijono, M; WoldeMussie, E, 2001) |
| "Preglaucomatous DBA/2J mice received memantine (5 mg/kg, intraperitoneal injection, twice daily for 3 months) and IOP in the eyes was measured monthly." | 3.75 | Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. ( Angert, M; Duong-Polk, KX; Ellisman, MH; Ju, WK; Kim, KY; Lindsey, JD; Weinreb, RN, 2009) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 3.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Retinal ischemia increased vitreous concentrations of glutamate and glycine." | 3.70 | Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. ( Bach, M; Feuerstein, TJ; Knörle, R; Lagrèze, WA, 1998) |
| "In the memantine group 47% of the neurons survived ischemia, in the cerestat group 61%, and in the riluzole group 43%." | 3.70 | [Neuroprotection in ischemia of the retina in an animal model]. ( Feuerstein, TJ; Lagrèze, WA; Otto, T, 1999) |
| "POAG patients appear to have a genetic predisposition rendering them susceptible to ROS-induced damage because of a more frequent deletion, as compared to controls, of the gene encoding for glutathione-S-transferase M1, a pivotal anti-oxidant activity." | 2.43 | [Open angle glaucoma: epidemiology, pathogenesis and prevention]. ( De Flora, S; Di Marco, B; Izzotti, A; Saccà, S, 2006) |
| "Treatment with memantine resulted in a significant reduction in RGC loss and NR1 expression in the eyes of rats COHT." | 1.34 | Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension. ( Jung, SW; Kim, JH; Lee, NY; Park, CK, 2007) |
| "Memantine was administered with the perfusate (simulated systemic access), by an intravitreal injection and by topical infusion." | 1.33 | Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye. ( Hughes, PM; Koeberle, MJ; Skellern, GG; Wilson, CG, 2006) |
| "Treatment with memantine à 20 mg/d lasted for 6 months and was preceded by one week à 10 mg/d." | 1.31 | [Use of memantine in progressive glaucoma. Case report]. ( Erb, C; Schröder, A, 2002) |
| " Daily oral dosing for approximately 15 months with 4." | 1.31 | Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. ( Chun, T; Feldmann, B; Hare, W; Lai, R; Ruiz, G; Ton, H; Wheeler, L; Wijono, M; WoldeMussie, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 13 (65.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinreb, RN | 5 |
| Liebmann, JM | 1 |
| Cioffi, GA | 1 |
| Goldberg, I | 1 |
| Brandt, JD | 1 |
| Johnson, CA | 1 |
| Zangwill, LM | 1 |
| Schneider, S | 1 |
| Badger, H | 1 |
| Bejanian, M | 1 |
| Atorf, J | 1 |
| Scholz, M | 1 |
| Garreis, F | 1 |
| Lehmann, J | 1 |
| Bräuer, L | 1 |
| Kremers, J | 1 |
| Ju, WK | 2 |
| Kim, KY | 2 |
| Noh, YH | 1 |
| Hoshijima, M | 1 |
| Lukas, TJ | 1 |
| Ellisman, MH | 2 |
| Perkins, GA | 1 |
| Angert, M | 1 |
| Duong-Polk, KX | 1 |
| Lindsey, JD | 1 |
| Gabelt, BT | 1 |
| Rasmussen, CA | 1 |
| Tektas, OY | 1 |
| Kim, CB | 1 |
| Peterson, JC | 1 |
| Nork, TM | 1 |
| Ver Hoeve, JN | 1 |
| Lütjen-Drecoll, E | 1 |
| Kaufman, PL | 1 |
| Schröder, A | 1 |
| Erb, C | 1 |
| Hare, WA | 2 |
| WoldeMussie, E | 3 |
| Lai, RK | 1 |
| Ton, H | 3 |
| Ruiz, G | 3 |
| Chun, T | 2 |
| Wheeler, L | 3 |
| Wijono, M | 2 |
| Feldmann, B | 2 |
| Zangwill, L | 1 |
| Sawaguchi, S | 1 |
| Greenfield, DS | 1 |
| Girkin, C | 1 |
| Kwon, YH | 1 |
| Yücel, YH | 1 |
| Gupta, N | 1 |
| Zhang, Q | 1 |
| Mizisin, AP | 1 |
| Kalichman, MW | 1 |
| Izzotti, A | 1 |
| Di Marco, B | 1 |
| De Flora, S | 1 |
| Saccà, S | 1 |
| Koeberle, MJ | 1 |
| Hughes, PM | 1 |
| Skellern, GG | 1 |
| Wilson, CG | 1 |
| Zhong, L | 1 |
| Bradley, J | 1 |
| Schubert, W | 1 |
| Ahmed, E | 1 |
| Adamis, AP | 1 |
| Shima, DT | 1 |
| Robinson, GS | 1 |
| Ng, YS | 1 |
| Kim, JH | 1 |
| Lee, NY | 1 |
| Jung, SW | 1 |
| Park, CK | 1 |
| Osborne, NN | 1 |
| Herrera, AJ | 1 |
| Lagrèze, WA | 2 |
| Knörle, R | 1 |
| Bach, M | 1 |
| Feuerstein, TJ | 2 |
| Otto, T | 1 |
| Hare, W | 1 |
| Lai, R | 1 |
| Pop, E | 1 |
2 reviews available for memantine and Intraocular Pressure
| Article | Year |
|---|---|
[New informations on medical treatment for normal-tension glaucoma].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Filtering Surgery; G | 2004 |
[Open angle glaucoma: epidemiology, pathogenesis and prevention].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aqueous Humor; Calcium Channel Blockers; DNA Damage; | 2006 |
1 trial available for memantine and Intraocular Pressure
| Article | Year |
|---|---|
Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind | 2018 |
17 other studies available for memantine and Intraocular Pressure
| Article | Year |
|---|---|
Functional protective effects of long-term memantine treatment in the DBA/2J mouse.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Electroretinography; Female; Follow-Up Studies; Gl | 2013 |
Increased mitochondrial fission and volume density by blocking glutamate excitotoxicity protect glaucomatous optic nerve head astrocytes.
Topics: Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Animals; Astrocytes; Cell Count; Cells, Cultured; E | 2015 |
Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Survival; Cytochromes c; Dyn | 2009 |
Structure/function studies and the effects of memantine in monkeys with experimental glaucoma.
Topics: Animals; Axons; Case-Control Studies; Disease Models, Animal; Evoked Potentials, Visual; Excitatory | 2012 |
[Use of memantine in progressive glaucoma. Case report].
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Evoked Potentials, Visual; Exc | 2002 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.
Topics: Administration, Oral; Animals; Cell Count; Chronic Disease; Disease Models, Animal; Electroretinogra | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.
Topics: Administration, Oral; Animals; Cell Count; Cell Survival; Disease Models, Animal; Excitatory Amino A | 2004 |
Memantine and progressive glaucoma.
Topics: Aged; Complementary Therapies; Disease Progression; Excitatory Amino Acid Antagonists; Female; Filte | 2005 |
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni | 2006 |
Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye.
Topics: Animals; Arteries; Blood Pressure; Cattle; Chromatography, High Pressure Liquid; Excitatory Amino Ac | 2006 |
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Topics: Animals; Axons; Cell Survival; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Techniqu | 2007 |
Expression of N-methyl-d-aspartate receptor 1 in rats with chronic ocular hypertension.
Topics: Analysis of Variance; Animals; Cell Death; Disease Models, Animal; Excitatory Amino Acid Antagonists | 2007 |
The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amin | 1994 |
Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia.
Topics: Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Excitatory Amino | 1998 |
[Neuroprotection in ischemia of the retina in an animal model].
Topics: Animals; Intraocular Pressure; Ischemia; Male; Memantine; Neuroprotective Agents; Rats; Rats, Spragu | 1999 |
Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey.
Topics: Animals; Cell Count; Cell Survival; Electroretinography; Evoked Potentials, Visual; Excitatory Amino | 2001 |
Trends in neuroprotection.
Topics: Aged; Amlodipine; Animals; Antiparkinson Agents; Apoptosis; Brain Diseases; Calcium Channel Blockers | 2002 |